Malin Corporation plc announced the appointment of Dr. Andrew von Eschenbach as Chief Medical Adviser, effective immediately. Dr. von Eschenbach previously served as an advisory partner to Malin. Dr. von Eschenbach is currently the president of Samaritan Health Initiatives Inc, and serves as an adjunct professor at Houston's University of Texas MD Anderson Cancer center. He is also a member of the Prostate Cancer Foundation Board of Directors and a Senior Fellow at the Milken Institute, a non-profit think tank. As Malin's Chief Medical Adviser, Dr. von Eschenbach will work with the management team and the company's therapeutic assets, with an initial focus on oncology and immuno-oncology related companies, including Poseida and Immunocore.